Related Experiment Video
Updated: Jun 10, 2026

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
Interpreting adverse drug reaction (ADR) reports as hospital patient safety incidents
Emma C Davies1, Christopher F Green, David R Mottram
1The Royal Liverpool and Broadgreen University Hospitals Trust, Prescot Street, Liverpool L7 8XP, UK. edavies@liverpool.ac.uk
What Is Already Known About This Subject:
Adverse drug reactions (ADRs) are a reporting category in the National Patient Safety Agency (NPSA) incident reporting system, though the Medicines and Healthcare Products Regulatory Agency (MHRA) pharmacovigilance system is the more established method for collecting ADR data.
What This Study Adds:
The majority of ADRs were shown to be of moderate risk to the patient, though some have a severe or catastrophic impact. Classification and reporting of ADRs according to NPSA guidance is possible but offers limited additional value to efforts to improve patient safety over and above the Yellow Card Scheme.
Aim:
In the UK, the National Patient Safety Agency (NPSA) includes adverse drug reactions as a reporting category, while the MHRA Yellow Card Scheme also collects data regarding adverse drug reactions (ADRs). In this study, we aimed to assess ADRs using NPSA criteria and discuss the resulting implications.
Methods:
ADRs identified in a 6-month prospective study of 3695 inpatient episodes were assessed according to their impact on the patient and on the organization, using tools developed by the NPSA.
Results:
Seven hundred and thirty-three (100%) ADRs were assessed. In terms of impact on the patient, 537 (73.3%) were categorized as 'low' (minor treatment), 181 (24.7%) as 'moderate' (moderate increase in treatment, no permanent harm), 14 (1.91%) as 'severe' (permanent harm) and 1 (0.14%) was categorized as 'catastrophic' (direct cause of death). In terms of impact on the organization, none was categorized as 'no harm/no risk', 508 (69.3%) as 'insignificant', 188 (25.6%) as 'minor', 25 (3.4%) as 'moderate', 12 (1.6%) as 'major' and none was classed as 'catastrophic'. Less than 2% of ADRs would be eligible for detailed analysis according to the NPSA guidance. The ADRs that cause incidents of greater significance relate to bleeding, renal impairment and Clostridium difficile infection.
Conclusions:
Classification of ADRs according to NPSA guidance offers limited additional value over and above that offered by the Yellow Card System. A consistent message needs to be sent to prospective reporters of ADRs; the availability of more than one system is likely to confuse reporters and does not aid patient safety.
Insights
Adverse drug reactions (ADRs) assessed by NPSA criteria showed most were moderate risk. However, NPSA classification offers limited extra patient safety value beyond the established MHRA Yellow Card Scheme.
Area of Science:
- Pharmacovigilance
- Patient Safety
- Drug Safety Monitoring
Background:
- Adverse drug reactions (ADRs) are a reporting category within the UK's National Patient Safety Agency (NPSA) system.
- The Medicines and Healthcare Products Regulatory Agency (MHRA) pharmacovigilance system, specifically the Yellow Card Scheme, is the primary method for collecting ADR data.
Purpose of the Study:
- To assess ADRs using NPSA criteria in a UK inpatient setting.
- To evaluate the implications of using NPSA criteria for ADR reporting and patient safety.
Main Methods:
- A 6-month prospective study involving 3695 inpatient episodes.
- Assessment of identified ADRs using NPSA tools, evaluating patient and organizational impact.
Main Results:
- Out of 733 assessed ADRs, 73.3% were low impact, 24.7% moderate, 1.91% severe, and 0.14% catastrophic for patients.
- Less than 2% of ADRs met NPSA criteria for detailed analysis.
- Significant ADRs were associated with bleeding, renal impairment, and Clostridium difficile infection.
Conclusions:
- Classification of ADRs using NPSA guidance provides minimal additional benefit compared to the MHRA Yellow Card Scheme.
- The existence of multiple reporting systems may confuse healthcare professionals and hinder patient safety efforts.
- A unified reporting message is recommended to improve ADR data collection and patient safety.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Types of Reports II: Incident or Occurrence Report
Purposes:
In the healthcare industry, reports play a crucial role in documenting incidents within an agency. The primary objective of these reports is to ensure patient safety, uphold the...
Drug Toxicity: Risk factors
Pharmaceutical Poisoning: Potential Scenarios
Drug Toxicity: Overview
Types of Reports III: Telephone and Verbal Reports
Here's an overview of each type:
Telephone Orders